🔹 Revenue at ₹1,565 Cr, down 12% YoY due to weak global agrochemical demand. 🔹 EBITDA declined 26% YoY to ₹337 Cr, while margin remained healthy at 22%. 🔹 PAT came at ₹200 Cr, down 39% YoY. 🔹 Export business declined amid global industry slowdown, while domestic business faced pricing pressure and lower crop acreage. 🔹 Pharma business remained strong with 23% YoY growth in Q4 and 40% growth in FY26. 🔹 Gross margin improved to 58% supported by favorable product mix and cost discipline. 🔹 FY26 Revenue stood at ₹6,714 Cr (↓16% YoY), while PAT came at ₹1,321 Cr (↓20% YoY). 🔹 Company commercialized 5 new molecules and launched 4 domestic products during FY26. 🔹 Strong balance sheet with surplus cash of ₹3,426 Cr and continued investment in R&D, Biologicals and Pharma CRDMO. 🔹 Management remains positive on FY27 with 5+ new molecule launches planned and strong order book visibility. ⚠️ Disclaimer: This post is for educational purposes only and not investment advice. Securities market investments are subject to market risks. Like, Follow & Share for more updates 🚀

PIIND

#StockInNews#WatchOutFor#FundamentalViews#Post-ClosingCommentary#EquityResearch

724 likes·62 comments